Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lurbinectedin |
Synonyms | |
Therapy Description |
Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lurbinectedin | Zepzelca | PM01183 | Chemotherapy - Alkylating 18 | Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06681220 | Phase II | Lurbinectedin Niraparib + Temozolomide | Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (Relapsed SCLC) | Not yet recruiting | USA | 0 |
NCT05740566 | Phase III | Lurbinectedin Topotecan Amrubicin Tarlatamab | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT06228066 | Phase II | Avelumab + Lurbinectedin Lurbinectedin | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | Recruiting | USA | 0 |
NCT05734066 | Phase Ib/II | Lurbinectedin | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (EMERGE 101) | Recruiting | USA | CAN | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT06203210 | Phase III | Ifinatamab deruxtecan Amrubicin Lurbinectedin Topotecan | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
NCT01525589 | Phase II | Lurbinectedin | A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | Completed | USA | ESP | 0 |
NCT01405391 | Phase I | Lurbinectedin | Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks | Completed | USA | 0 |
NCT05918640 | Phase Ib/II | Lurbinectedin | Lurbinectedin in FET-Fused Tumors (LiFFT) | Recruiting | USA | 0 |
NCT06217536 | Phase Ib/II | Lurbinectedin | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Withdrawn | 0 |